Brian T Bateman1, Elisabetta Patorno2, Rishi J Desai2, Ellen W Seely3, Helen Mogun2, Ayumi Maeda4, Michael A Fischer2, Sonia Hernandez-Diaz5, Krista F Huybrechts2. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Anesthesiology, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and bbateman@partners.org. 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and. 3. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4. Department of Anesthesiology, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: β blockers are widely used in the treatment of hypertensive disorders during pregnancy. These medications cross the placenta and may cause physiologic changes in neonates exposed in utero. We sought to define the risks of neonatal hypoglycemia and bradycardia associated with maternal exposure to β blockers at the time of delivery in a large, nationwide cohort of Medicaid beneficiaries. METHODS: We used a cohort of 2 292 116 completed pregnancies linked to liveborn infants of Medicaid-enrolled women from 2003 to 2007. We examined the risks of neonatal hypoglycemia and neonatal bradycardia associated with maternal exposure to β blockers at the time of delivery. Propensity score matching was used to control for potential confounders including maternal demographics, obstetric and medical conditions, and exposure to other medications. RESULTS: There were 10 585 (0.5%) pregnancies exposed to β blockers at the time of delivery. The risk of neonatal hypoglycemia was 4.3% in the β blocker-exposed neonates versus 1.2% in the unexposed; the risk of neonatal bradycardia was 1.6% in the exposed versus 0.5% in the unexposed. After controlling for confounders, risk remained elevated for both neonatal hypoglycemia and bradycardia among exposed pregnancies versus unexposed (adjusted odds ratio, 1.68, 95% confidence interval, 1.50-1.89 and adjusted odds ratio, 1.29, 95% confidence interval, 1.07-1.55, respectively). CONCLUSION: Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia.
BACKGROUND AND OBJECTIVES: β blockers are widely used in the treatment of hypertensive disorders during pregnancy. These medications cross the placenta and may cause physiologic changes in neonates exposed in utero. We sought to define the risks of neonatal hypoglycemia and bradycardia associated with maternal exposure to β blockers at the time of delivery in a large, nationwide cohort of Medicaid beneficiaries. METHODS: We used a cohort of 2 292 116 completed pregnancies linked to liveborn infants of Medicaid-enrolled women from 2003 to 2007. We examined the risks of neonatal hypoglycemia and neonatal bradycardia associated with maternal exposure to β blockers at the time of delivery. Propensity score matching was used to control for potential confounders including maternal demographics, obstetric and medical conditions, and exposure to other medications. RESULTS: There were 10 585 (0.5%) pregnancies exposed to β blockers at the time of delivery. The risk of neonatal hypoglycemia was 4.3% in the β blocker-exposed neonates versus 1.2% in the unexposed; the risk of neonatal bradycardia was 1.6% in the exposed versus 0.5% in the unexposed. After controlling for confounders, risk remained elevated for both neonatal hypoglycemia and bradycardia among exposed pregnancies versus unexposed (adjusted odds ratio, 1.68, 95% confidence interval, 1.50-1.89 and adjusted odds ratio, 1.29, 95% confidence interval, 1.07-1.55, respectively). CONCLUSION: Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia.
Authors: Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn Journal: Med Care Date: 2007-10 Impact factor: 2.983
Authors: Laura A Magee; Peter von Dadelszen; Evelyne Rey; Susan Ross; Elizabeth Asztalos; Kellie E Murphy; Jennifer Menzies; Johanna Sanchez; Joel Singer; Amiram Gafni; Andrée Gruslin; Michael Helewa; Eileen Hutton; Shoo K Lee; Terry Lee; Alexander G Logan; Wessel Ganzevoort; Ross Welch; Jim G Thornton; Jean-Marie Moutquin Journal: N Engl J Med Date: 2015-01-29 Impact factor: 91.245
Authors: Susan E Andrade; Marsha A Raebel; Jeffrey Brown; Kimberly Lane; James Livingston; Denise Boudreau; Sharon J Rolnick; Douglas Roblin; David H Smith; Gerald J Dal Pan; Pamela E Scott; Richard Platt Journal: Pharmacoepidemiol Drug Saf Date: 2008-03 Impact factor: 2.890
Authors: Emily W Y Tam; Elysa Widjaja; Susan I Blaser; Daune L Macgregor; Prakash Satodia; Aideen M Moore Journal: Pediatrics Date: 2008-09 Impact factor: 7.124
Authors: Rishi J Desai; Krista F Huybrechts; Sonia Hernandez-Diaz; Helen Mogun; Elisabetta Patorno; Karol Kaltenbach; Leslie S Kerzner; Brian T Bateman Journal: BMJ Date: 2015-05-14
Authors: Brian T Bateman; Sonia Hernandez-Diaz; Michael A Fischer; Ellen W Seely; Jeffrey L Ecker; Jessica M Franklin; Rishi J Desai; Cora Allen-Coleman; Helen Mogun; Jerry Avorn; Krista F Huybrechts Journal: BMJ Date: 2015-03-17
Authors: Kathryn Rough; Jenny W Sun; George R Seage; Paige L Williams; Krista F Huybrechts; Brian T Bateman; Sonia Hernandez-Diaz Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Sorcha A Collins; Gertrude Elizabeth Hildes-Ripstein; James Robert Thompson; Sharon Edmunds; Amber Miners; Cheryl Rockman-Greenberg; Laura Arbour Journal: Paediatr Child Health Date: 2020-04-03 Impact factor: 2.253